6^th European Conference on Predictive , Preventive and Personalized Medicine & Molecular Diagnostics September 14-15, 2017 Edinburgh, Scotland

Biography:

Paola Cardenas is a dermatologist from National University of Colombia, master in public health and master in cutaneous oncology from Valencia University (Spain) at the Valencia Institute of Oncology. She is the director of the skin cancer program at Virrey Solis Hospital in Bogota Colombia. She works as an associated professor in the dermatology program at National University of Colombia. She has published more than 10 papers in reputed national and international journals.

Abstract:

Serum levels of S100B protein are widely used  as a marker for malignant melanoma, and correlation between serum S100B and disease relapse and survival has been reported. During regular follow-up of patients with malignant melanoma transient elevation of serum S100B protein are observed but the clinical significance of this elevations is unknown. The primary aim of the study was to investigate the correlation between transient elevations of serum S-100B protein and the relapse risk of malignant melanoma.

Between 2006 and 2015, 428 consecutive AJCC stage I, II, III clinically disease free melanoma patients, with serum S100B evaluations and followed for at least 5 years were included in this retrospective study.  Relapse occurred in 40.3% of the patients (n=174) during a median follow up period of 70 months. By univariate analysis, transient S-100B elevations were associated with significant relapse risk (p<0.001). Multivariate analysis was performed adjusting for significant prognostic factors (ulceration and TNM) and the transient S100B elevations remained as a significant and independent prognostic factor for relapse (HR  3.18, 95% IC  1.89-5.37; p<0.001).

Transient S100B elevation is a significant and independent prognostic factor for relapse in melanoma patients. Therefore the S100B may be useful in the follow-up of disease free stage I , II  and III melanoma patients and the detection of the elevated S-100B levels  maybe lead to closer monitoring in follow-up and possibly earlier aggressive surgical or medical treatment of recurrences. To the authors knowledge, the current study is the first evaluation of the S100 B serum transient elevations as a prognostic factor for relapse

Biography:

Giath Osman has completed his Bachlore degree in medicine and surgery from univesity of Mousel medical school in 1984,He is American Board certified In vascular and General Surgery ,Fellow of the Royal College of Surgeons Of Ireland and Has Advanced fellowship Training in Minimal Invasive and Bariatric Surgery in the United States,He is an Activily Practising surgeron through his Private Prcatice and is affliated with George Washington Univesity Hospital in Washington Dc anD Inova Health Sytem in virginia.. He has published in reputed journals and has presented at multiple national and Intrenational conferances

Abstract:

Obesity and Morbid Obesity with its common morbiditis and mortalities is an endimic diease entity in the united states, and it is changing into an epidemic medical problem all over the world,Medical managmnet including dietary and life style modification has not been very susseful as a long term mangmnet tool,Surgical invervention on the other hand in aditions to its surgical complication riscks is associated some times with some unoptimal results and gain of weight after the surgical procedure.Ghreelin hormone reduction surgical procedures might be the start of anew era in the mangment of Obesity and morbid obesity.Im sure of that we all have  noticed an individual or a family member who is described as the lucky one because he or she eats what ever they like and never put on weight during their life cycle,what secret do those indivivuals posses which gives them this unique ability to keep their weight in a healthy range during their life .Can we discover their secret.What can we learn from their metabolic machine. Im going to present a resarch project structure which will eventually individualize and personalize the mangmnet of Morbid obesity and possiblity help in maintaing the weight loss in those individuals

Biography:

Deputy Head, Cardiovascular Center, 1st School of Medicine, Charles University, Prague,Main topics of interest: interventional cardiology, pulmonary circulation, published more then 400 articles in cardiology journals all over the world.Editor-in Chief, Cor et Vasa, the official Journal of Czech Society of Cardiology.Member of the Board of  Czech Society of Cardiology, European Socienty of Cardiology, International Andreas Gruentzig Society, Council on Thrombosis and Hemostasis, International Society and Federation of Cardiology.Awards: Medal for Life Work from President of Czech Republic – 2009

Abstract:

First percutaneous balloon coronary angioplasty was performed by Andreas Grüntzig on September 16, 1977 in Curych, Switzerland. His pioneer work started new era of coronary revascularisation all over the world. Since then, interventional cardiology began to grow immensly with new development in several topics: materials, technique of interventions, indications, type of lesions, restenosis prevention and treatment, stents, drug eluting stents, as well as drug treatment focused on early and late thrombosis after interventions. From clinical point of view interventions started with patients with chronic coronary artery disease, but moved further into the field of acute coronary syndromes, including acute myocardial infarction with ST segment elevations. Currently, coronary interventions are quite common way of treatment of coronary artery disease, with hundreds of thousands of procedures performed every year in Europe, as well as in other parts of the world

Biography:

Adla Bakri Hassan is MD (Sudan), MPhil (Sweden), PhD (Sweden), PGDip (MSK US, Spain),She graduated from Gezira University in Sudan. She did her postgraduate studies and training at Karoliniska Institute and Karoliniska Hospital in Sweden, also at Hope Hospital in United Kingdom. She has experiences over 20 years in different hospitals and countries treating rheumatic disease patients; Sudan, Sweden, UK and Bahrain. She has over 10 years’ experience in teaching medical students. She is currently working as Assistant Professor in the department of internal medicine at Arabian Gulf University (AGU) in Kingdom of Bahrain and as Consultant Rheumatologist at the University Medical Centre (UMC). She is a Reviewer and has over 20 publications in peer-reviewed journals

Abstract:

Abstract

Introduction: The relationships between serum levels of Uric Acid (UA) and vitamin D3 (25-OH Cholecalciferol) in systemic lupus erythematosus (SLE) have been revealed separately; however, a possible link between these two factors and their interaction with SLE severity has not been clarified yet. This is the first study on investigating the conjoint association of vitamin D3 and UA on disease activity in Bahraini patients with SLE.

Objectives: To evaluate serum UA and serum vitamin D3 (VD) as important factors in clinical status in adult Bahraini patients with SLE and to look into the possible correlation between these two factors and their relation to disease activity in this patient’s group.

Materials & Methods: 51 adult Bahraini SLE patients (mean age of 40.8 years, females were 84.3%) were included in this retrospective longitudinal (two-time points) study. Blood samples were taken before and after VD therapy 2-3 months apart at Salmanyia Medical Complex. All patients received oral VD therapy in form of tablets (50.000 IU) once per week for a maximum period of 3 months. Blood samples were obtained for determination of serum levels of VD, calcium, phosphorus, alkaline phosphatase (ALP) and parathyroid hormone (PTH), but also for serum UA, complements (C3&C4), C-reactive protein (CRP), antinuclear antibodies (ANA) and anti-double-stranded (ds)- DNA antibody.

Results: The current study showed that VD therapy brings about two fold increment in its mean serum level (P<0.0001) with increased in serum calcium (P<0.05). Wonderfully, the mean serum levels of ds-DNA auto-antibodies and UAUA were significantly decreased after VD therapy (p=0.015 and p=0.010, respectively). Interestingly, when the group was segregated by gender and age; the female group and the age group < 40 years, independently, showed statistically significant difference in all parameters exactly as the whole group. Comparably, both the male group and the age group ≥ 40 years showed notable reduction in mean serum UA, but that was statistically not significant.

Conclusion: We evaluated serum UA and serum VD as important factors in SLE disease. Our study showed strong inverse correlation between these two factors, thus, the correction of hypovitaminosis in SLE patients resulted in reduced serum UA. The current study established that serum VD levels are inversely correlated with both serum uric acid and disease activity, undependably, in adult Bahraini patients with SLE. Consequently, we strongly recommend VD supplementation for Bahraini patients with SLE.

Biography:

Goncharova Elena has completed her PhD at FBRI State Research Center of Virology and Biotechnology “Vector”. She is the senior researcher of Institute of Chemical Biology and Fundamental Medicine, Siberian Branch of Russian Academy of Sciences, Russia. She has published more than 26 papers in reputed journals. Her research interests include oncolytic viruses, development of antiviral therapeutics and vaccines.

Abstract:

The development of novel drugs against the influenza virus with high efficiency and low toxicity is an urgent and important task. Herein, we investigated the antiviral potential and a mechanism of antiviral activity of novel sulfonated derivative of β-cyclodextrin [(Gluox)₇-С₁₄]-(SO₃Na)₁₄ (SCD) against influenza virus A/WSN/33 (H1N1) in vitro and in vivo. The cytotoxicity of SCD examined with respect to uninfected MDCK and A549 cells was shown to be quite low: IC₅₀ values corresponding to survival of 50% cell population were 15±3.3 and 11.5±0.8 mg/mL for MDCK and A549 accordingly. Antiviral potential of SCD was evaluated in MDCK cells treated with serially diluted compound simultaneously with inoculation of the influenza virus. Quantification of virus titers 48 h post infection showed that influenza virus replication had been severely affected. We showed that SCD possesses virulicidal activity and virus was entirely inactivated after incubation with the compound for 6 h at 37°C. Incubation virus particles with SCD did not block neuraminidase activity but resulted in decreasing of virus hemagglutinin activity. The results of the time-of-addition assay suggested that SDC inhibited virus replication only after incubation of infected cells with the compound. The in vitro antiviral effects of SCD were confirmed in a murine pneumonia model of influenza. Our data showed that intranasal treatment of mice with SCD protected the animals from lethal infection and significantly decreased viral titers in lungs of infected animals. Therefore, SCD is promising candidates for the development of antiviral drugs for prevention and treatment of influenza infection

Biography:

He have a long career as a leader in the pharmaceutical industry at Director level or above and he is the founder of Woodland Pharmaceuticals.He is passionate about advancing treatment of the deadliest cancers. Our team’s approach involves building relevant in vitro and in vivo models and my focus over the past 10 years has been to increase the likelihood of effective translation to the clinic by establishing primary patient tumor models that are much closer to the patient tumor biology than the traditional cancer cell lines. The highest unmet medical need in oncology therapy is cancer recurrence.   Our ultimate goal is to move to experimental systems using patient-derived tumor models that better inform us of the diversity we are likely to see in the clinic, thus improving clinical outcomes to positively impact patient health and make the drug discovery process more productive and efficient.  The idea is to test the prospective drug in low passage patient tumor samples before we get to the clinical trial, and thus may be likened to a “preclinical trial”. 
 

Abstract:

We developed a mouse avatar technology which involves capturing, expanding, characterizing and viably freezing primary patient tumors at low passage number to better model long-term treatment and recurrence of solid tumors as similar to the patient as possible. Through long-term dosing we are able to generate refractory tumor models resistant to normally efficacious drugs.  Our process can take more than 100 days of treatment to generate drug-resistant models in vivo.  Currently, we implant cells or tumor pieces sourced from patient-derived primary resection.  These models are incredibly powerful when used for molecular profiling to better understand predictive markers of progressive, metastatic, refractory disease, and also empirically as tools for drug discovery. It is our belief that testing new cancer therapies being developed against the very same drug-resistant tumors they are most likely to face in early clinical trials will provide a new level of translational success to future oncology drug discovery programs and improve patient experience in clinical trials

Biography:

Antonina Sidoti was born in Messina, Italy. She obtained her degree in “Biological Sciences” (1992), magna cum laude, at the University of Messina, Italy. In 1993 she obtained professional qualifi cation and registration in the National Board of Biologists. Following a four years specialization course, she obtained in 1997 at the University of Messina, the specialization degree in“Clinical Pathology”. In 1998 she was winner of a foreign study scholarship held in Paris at the Biology LabnMolecular and Genetic Prof. Luc Montagnier, "Center Integré de RecherchesBiocliniques sur le Sida ".In 1999 she obtained PhD in “Cellular Biology and Genetics”, University of Messina. In 1999-2000 she partecipated to a selection for University Researcher at the Medical School of the University of Messina: She won the selection and became University Researcher, in the fi eld of Applicated Biology (BIO/13). Currently sheis Associated Professor in Applied Biology and Chairman of master's degree course in “Biotechnology for the Health” of University of Messina, Italy. She plays her teaching activity in Degree in Medicine, Biotechnology and other degrees of same University. Actually her main research field is related to molecular and genetics features of Cerebral Cavernous Malformations; identifi cation of candidate genes and causative variants in different forms of Retinitis Pigmentosa and moleculargenetic features and genotype-phenotype correlations in Trimethylaminuria.

Abstract:

Cerebral Cavernous Malformations (CCM) are vascular lesions involving brain capillaries. CCM is considered a rare genetic disorder however, its incidence is underestimated. Many cases, instead, are post-mortem accidentally detected, being asymptomatic about 30% of affected. Most common clinical manifestations include intracerebral hemorrhage, seizures, focal neurological deficits. Resonance Magnetic Image (RMI) performed with “gradient-echo” sequences is the most effective diagnostic method. CCM can arise sporadically or be inherited as autosomal dominant character leading to onset of familiar forms. Mutations at the three loci CCM1/KRIT1, CCM27MGC4607, CCM3/PDCD10 were detected in about 90% and 55% of patients affected by familial and sporadic forms, respectively. In the last 10 years, more than 100 CCM cases arrived to our laboratory for molecular diagnosis. Our diagnostic procedure includes both direct sequencing and Multiplex Ligation-Dependent Probe Amplification (MLPA) performed for the three CCM genes on DNA sample extracted from peripheral blood, in order to detect point mutations or large genomic rearrangement, respectively. About mutations frequencies, our data overlap with literature’s ones. However, we noticed recurrent polymorphisms overall in CCM1 and CCM2 genes. Several case-control studies were performed and  rs17164451,  rs11542682  in  CCM1  and  rs11552377,  rs73107990,  rs2289367  in  CCM2 resulted associated with an increased risk of sporadic CCM development. Moreover, several  were detected in patients showing more severe symptomatology. Therefore, our aim is to integrate anamnesis and RMI data with genetic test results in order to establish possible genotype-phenotype correlations usable both as follow-up route for patients and as prognostic factors for their relatives

Biography:

She working in the Department  of  Molecular  Oncology  at  King  Faisal  Specialist  Hospital  and  Research Center (KFSHRC) Hospital, SA. One of the co-founders of the Zahra Breast Cancer Association and a member of its scientific committee and Associate Professor in the College of Medicine at Al-Faisal University. she is graduated from the Medical School at UCL-UK and have been working since 2000 in the Oncology Department at King Faisal Specialist Hospital and Research Center at KFSHRC Hospital

Abstract:

To date, several genetic, epigenetic and proteinaceous biomarkers have been found to be associated with breast cancer, but their robustness as indicators of disease remains uncertain. More significantly, most women in the developing countries present with this cancer only when it has reached an advanced stage. The treatment of advanced stage presents several challenges but most important among them is the frequent development of resistance to chemotherapy and hormonal therapy which leads to a high mortality rate. In light of this, there is a need to identify sensitive biomarkers that could be useful in early detection and in following the progression of the disease; these might help to identify new therapeutic targets. MicroRNAs (miRs) form a class of non-coding RNA that regulates post-transcriptional gene expression and thereby cellular processes. In breast cancers, dysregulation of the miRs’ expression can result in the progression of cancers. In addition, miRs have been shown to play a role in the development of resistance to drug therapy by regulating signalling cascades. From a cohort of 100 disease-free individuals and 127 breast cancer patients; the levels of these circulating miRNAs are being verified by qRT-PCR. The results of this part have shown over-expression of some types of miRs in the breast tumour patients, while the levels of others remain lower than those in normal individuals. Another interesting pattern emerged when we compared the relative levels of these circulating miRNAs with their expression levels in breast tissue. In addition to intergroup comparisons, plasma miRNA expression levels of all groups were analyzed against cancerous breast tissue (RNA-Seq data from The Cancer Genome Atlas-TCGA). A differential set of   miRNAs were identified in the plasma of breast cancer patients   and

10 miRNAs were uniquely identified based on ROC analysis. The most striking findings  revealed elevated some of the tumor suppressor miRs in luminal breast cancer patients plasma, irrespective of subtype, and elevated in plasma of TNBC breast cancer patients. We found also that, while most miRNAs in plasma reflected cellular levels some of them, had an inverse pattern, thereby suggesting that they were being selectively secreted into plasma. The circulated miRNA patterns indicate signatures which could be as biomarkers for detection, with potential use in screening and in distinguishing the type of tumour type and also could be used as targets for therapies.

Biography:

S Suchkov graduated from Astrakhan State Medical University in 1980 and was awarded with MD. In 1985, he completed PhD from I M Sechenov Moscow Medical Academy and Institute of Medical Enzymology. In 2001, he completed his Doctor Degree at the National Institute of Immunology, Russia. From 1989 to 1995, he was Head of the Lab of Clinical Immunology, Helmholtz Eye Research Institute in Moscow. From 1995 through 2004, he is a Chair of the Dept. for Clinical Immunology, Moscow Clinical Research Institute (MONIKI). In 1993-1996, he was a Secretary-in-Chief of the Editorial Board, Biomedical Science, an international journal published jointly by the USSR Academy of Sciences and the Royal Society of Chemistry, UK. At present, he is Professor and Chair, Department for Personalized and Translational Medicine, I M Sechenov First Moscow State Medical University and Department of Clinical Immunology, A I Evdokimov Moscow State Medical and Dental University. He is a member of the Editorial Boards of Open Journal of Immunology, EPMAJ, American J of Cardiovascular Research and Personalized Medicine Universe.

Abstract:

A new systems approach to diseased states and wellness result in a new branch in the healthcare services, namely, personalized medicine (PM). To achieve the implementation of PM concept, it is necessary to create a fundamentally new strategy based upon the subclinical recognition of biopredictors of hidden abnormalities long before the disease clinically manifests itself.

Each decision-maker values the impact of their decision to use PM on their own budget and well-being, which may not necessarily be optimal for society as a whole. It would be extremely useful to integrate data harvesting from different databanks for applications such as prediction and personalization of further treatment to thus provide more tailored measures for the patients resulting in improved patient outcomes, reduced adverse events, and more cost effective use of health care resources. A lack of medical guidelines has been identified by the majority of responders as the predominant barrier for adoption, indicating a need for the development of best practices and guidelines to support the implementation of PM!

Implementation of PM requires a lot before the current model “physician-patient” could be gradually displaced by a new model “medical advisor-healthy person-at-risk”. This is the reason for developing global scientific, clinical, social, and educational projects in the area of PM to elicit the content of the new branch

Biography:

Tejashree received her Master's degree M. D. S in Oral medicine and Radiology from Maharashtra University of Health Sciences,  India in 2013. She joined Ragoonwala College of Dental Sciences in 2014 as a Senior Lecturer.  She also has an individual dental practise and Consults at various Dental Clinics in India.  Her focus is on diagnosis and management of Oral Diseases and Maxillofacial Radiology. She has published in reputed international journal and is also a Reviewer.  She has presented papers and posters at various conferences.  Her main research interest includes Oral Cancer and Advanced Imaging modalities

Abstract:

Early detection and treatment of oral carcinoma has an impact on survival rate. Therefore it is crucial to diagnose and image accurately. The pathologic prognostic implicators of oral carcinoma are tumor dimensions, thickness, margins and vasculariy. The rapidity, non-ionizing characteristics, non-invasiveness, less expensive technique, makes Ultrasound an ideal adjunctive pre-treatment assessment modality for staging and prognostic evaluation

Biography:

To be updated soon

Abstract:

Background: Even if patients with stage IV cancer (AC) may have prolonged remissions with chemotherapy (CT), the majority of them, will eventually relapse. In vitro studies suggest that natural killer (NK) cells mediate lytic activity against cancer cell lines and that high expression of vascular endothelial growth factor (VEGF) promotes tumor progression through neoangiogenesis. We have shown that low-dose interleukin-2 (IL-2) and 13-cis retinoic acid (RA) increased NK cells and decreased VEGF, in patients with AC and a clinical benefit on CT (Clin Cancer Res 7: 1251, 2001). We hypothesized that IL-2 and RA, increasing NK and decreasing VEGF, could improve disease-free survival (DFS) and overall survival (OS) in a minimal residual disease setting. Primary endpoint was the evaluation of NK cells and VEGF; secondary endpoints were DFS, OS and toxicity. 

Methods: 500 patients with stage IV cancer, who had had a clinical benefit from CT, were given immunotherapy in order to maintain response to CT. Imunotherapy consisted of subcutaneous IL-2, 1.8 X 10⁶ IU and oral RA, 0.5 mg/Kg for 5 days/week, 3 weeks/month, until progression. NK cells, VEGF, response and toxicity were assessed every 4 months.

Results: After a median follow-up of 112 months (range 63-200), a total of 4400 courses of chemotherapy and 2634 courses of immunotherapy were delivered. A statistically significant improvement of NK cells [from a mean of 309 ± 76/mm³ to a mean of 579 ± 74/mm³ (p < 0.001)] and a decrease of VEGF [from a mean of 520 ± 75 pg/mm³ to a mean of 150 ± 12 pg/mm³, (p < 0.001)], were observed. 18-years DFS and OS were 29% and 32%, respectively. A significant improvement, with respect to NCI SEER data (*), was observed in the 5-year OS rate for the most common treated AC: Breast cancer 55% vs. 6% *; Lung cancer 22% vs. 4.3% *; Colorectal cancer 43.5% vs. 21%*. No WHO grade 3 or 4 toxicity was observed, while grade 2 cutaneous toxicity and fever occurred in 20% and 13% of patients, respectively. 

Conclusions: Our data show that immunotherapy with IL-2/RA, may determine, with an acceptable toxicity profile, a statistically significant improvement of NK cells, a decrease of VEGF, and better 5-year survival rates with respect to NCI SEER data, for all major cancers.

Biography:

Thomas Werner is the chairman of the executive board of m4 Personalisierte Medizin .e.V., a charitable organization to further personalized medicine. He is also an adjunct professor at the Internal Medicine, Nephrology, University of Michigan in Ann Arbor, MI, USA. He received his PhD in 1986 and has authored more than 150 peer reviewed scientific articles and book chapters. He founded Genomatix Software GmbH in Munich 1997 and was the CEO and CSO of the company for more than 10 years. His research focus is on new approaches in translational and P4-medicine.

Abstract:

Preventive, predictive, personalized, and participatory medicine (P4-medicine) requires science, medicine, judicial, ethics, and the general public, including politics to cooperate. Only broad consent and support will allow making the necessary changes to our existing health care system. This will not only ensure better medical treatment for many of us, but also offers unique opportunities to combine improved health care with economic saving, mostly coming from the first part - preventive medicine. Challenges are the acquisition of large amounts of molecular data (genome sequences, tumor genomes, transcriptomes, and an ever growing amount of biomarkers) from patients and also from the healthy population. Once sufficient data are available, suitable consent forms must accompany them in order to allow comparative analysis on a sufficiently large scale. Especially the interpretation of -omics data still presents formidable problems we need to overcome, as will be illustrated in just one example. Results need to be stored and safeguarded properly in order to fulfill legal and ethical requirements of data protection. However, current limitations are often decades old and entirely oblivious of the requirements and possibilities of P4-medicine. Here we need sufficient general education to ensure that politician can remove some obstacles in tune with their electorate. This includes health care providers who often see P4-medicine just as another huge attack on their budgets. They need to realize the saving potential especially in prevention and early treatment of chronic diseases. We need viable economic models to demonstrate these effects as real. I will summarize what our association is doing in detail to help facilitate to required change of mind sets in order to make P4-medicine a reality for all of us.

Biography:

Girolamo Garreffa was Born in Genova (IT) in May 1959, in the 80s/90s he achieved the Master in Physics and a Professional Doctorate in Health/Medical Physics. Since 2001 to 2012 he was Senior Scientist in MR Physics and Leader of the project Magnetic Resonance and Brain Function at Centro di Studi e Ricerche E. Fermi in Rome. In the same period and up to now he covered  roles as MR Scientist and MRI Physicist in Hospital and Research Institutions among them: NEUROMED (Isernia, IT) Medical Imaging and Neurosurgery Departments; Santalucia Foundation (Rome, IT) Neuro Imaging Dept.; National Research Council (Cosenza, IT) Dept. of Neurological Sciences, University of Tor Vergata (Rome, IT) and Sapienza Univ. of Rome as Professor of  Medical and Applied Physics. Currently he is also MR Scientist at Fondazione Potito (Campobasso, IT), MR Scientist at ME.DI. Center (Napoli) and Head of Applied Physics Section at I.E.ME.S.T.(Palermo, IT).

Abstract:

The proposed study is based on a non-conventional use of advanced methods of MRI with the acquisition of a time series of ultrafast images with contrast weighted on dynamic blood oxygen level. A continuous acquisition is performed before, during and after the application of a standardized stimulus produced by a dedicated external mechanical device acting on the upper part of the ankle of  the foot under investigation. The simultaneous use of MRI compatible Near Infrared Spectroscopy (NIRS) detectors, placed on a given distance and position from the mechanical action and on the limb surface can be used to standardize the stimulus by controlling the oxy/deoxy hemoglobin ratio on a tissue volume below the NIRS detector. A dedicated analysis procedure to extract the time course of one or more regions of interest on the acquired MRI foot images, allows  to identify  the mechanical action phase on each related graph obtained. The curve is characterized by a flat portion for basal condition, a descending tract in correspondence of the onset of mechanical stimulus and of a recovery tract immediately after stimulus cessation. A suitable curve fitting of this recovery portion will provide a characteristic time constant directly representative, in its magnitude, of the possible incoming disease and if so, a powerful diagnostic non invasive tool can be realized not only in disease grade assessing but also for the follow-up, for example, to evaluate benefits after drug therapies studies. Preliminary results on health subjects support the feasibility of this investigation procedure

Biography:

James Russell obtained his PhD in Bioanalytical Chemistry from the University of Strathclyde in June 1994.  Then completed a NIH Postdoctoral fellowship at UC Riverside working on the thiol /disulfide chemistry of peptides in HIV conserved regions.  He spent 20 years at Gen-Probe Incorporated where he was responsible for numerous successful IVD products, including the first NAT test, used to screen the nation’s blood supply for HIV and Hepatitis. In 2016 he joined Thermo Fisher as a Senior Director in the R&D department working on Next Generation sequencing assays.

Abstract:

As progresses continue in the development of breakthrough immuno-therapy treatments, research to identify informative biomarkers becomes increasingly important. We are investigating multiple approaches to identify biomarkers that may be useful in current development efforts and potentially for stratification and/or therapeutic monitoring in the future. These and other projects aimed at helping to advance precision genomics will be discussed.

Biography:

Jan Kvasnicka aquired MD(1966) and PhD(1986) from Charles University at Prague, his  appoint-ment to Professor in this University was in 2002. He is  chairmen of Molecular Genetic Labortatory at Thrombosis Centre of General University Hospital in Prague. He has published more than 250 papers in reputed journals ( 51 with IF ), his citation index WOS SCI is 809 and hi-index is 15.

Abstract:

Proof of the role of platelets in VTE was provided by two randomized, double-blind trials, WARIS and ASPIRE. Both recently showed a reduction in venous thrombosis recurrence by approximately 30% with the use of the antiplatelet drug, aspirin, compared to placebo. The aim of our study (supported by grant RVO VFN 64165) was to parse the frequencies of selected polymorphisms in platelet genes associated with higher platelets activity in cohorts of patients with venous thromboembolisms. Genetic testing of polymorphisms (SNP) GPVI (Ser219Pro, rs1613662), P2Y12 (haplotype H1/H2, rs2046934; 32C>T, rs 6785930), GPIIIa (Leu59Pro, rs5918), GPIa (807C>T, rs1126643), COX-1 (-842A>C, rs10306114) and PAR-1 (IVS+141G>A), were completed for 2630 persons with VTE and control group of 2637 healthy persons without history of VTE. Results: The examination did not show any significant differences between the polymorphism frequencies in subjects with VTE in comparison to the results obtained in control group. But in the subgroup of women with VTE in pregnancy or in puerperium (n 161) was observed an increase of the risk allele T in GP Ia gene ( 807C>T , rs 1126643) with p = 0.049  ( after Bonferoni correction) and odds =1,513. Between these patients with finding of the risk allele T was observed significance of the next mutation of PAR-1 gene (IVS + 1411G>A) with p = 0.016 and odds =2.256. Conclusion: It is suggested that the observed platelet gene polymorphisms of GP Ia and PAR-1 play role in an increase of primary haemostasis activity in pregnancy as a cause of thrombophilia state, too.

Biography:

To be updated soon

Abstract:

As far as the contemporary immunological concepts are concerned, the followings are recognized as facts: (1) All of autoimmune diseases are caused by combinations of organ-specific antibodies and cytolytic T lymphocytes. (2) All of allergic diseases are caused by combinations of allergen-specific antibodies and mast cells. and (3) Equilibrium states exist among antibody molecules in the vicinity of their receptors on the surface of leucocytes. In my opinion, which occurred to me incidentally, an extremely useful point of view could be delineated. Namely, based on the existence of equilibrium state among antibody molecules in the vicinity of their receptors, replacements of specific antibodies with non-specific antibodies would be possible if the latter were accumulated in the vicinity of receptors of antibody molecules. In order to accumulate non-specific antibody molecules, a repetition of intradermal injections with a non-specific antigen preparation is necessary. As an alternative method, intra-venous infusions of saline solution of gamma-globulin might be suggested. However, this method is dangerous
because anti-gamma-globulin antibodies could be produced after a large number of its infusions and an anaphylactic reaction may occur.

Biography:

Anatolii Pavlenko has completed his PhD from Sevastopol Polytechnical Institute. He is the Director of “Spinor International”, Head of the Laboratory of the Electron Devices chair at Open International University of Human Development “Ukraine”,. He has published more than 50 papers in reputed journals and has been serving as a Member of the Editorial Boards of a scientific periodical: Ukrainian Journal  of Physical vacuum and Nature

Abstract:

New guidelines are proposed for medical  innovative approaches to early and predictive  targeted prevention in healthy individuals, persons at-risk, individuals, persons at-risk ets.

Techno pathogenic effect - a set of factors and processes that have any kind of negative effect or impact on living organisms resulting from scientific and technological progress of mankind.  It was determined that the installation of masts base stations and wind turbines at the intersection of the fault zones, which is a natural migration of groundwater, or geopathogenic zone, causes the appearance of artificial radiation of these zones and the spread of radiation occurs along areas faults or discontinuities along the axial in the soil. Constant exposure to natural and artificial radiations can cause changes in behavior, the state of aggression or depression (sometimes to the point of suicide), constant fatigue, sleep problems, partial loss of memory, problems with concentration, stress. All electronic devices generate a «torsion fields». Large amount of free radicals produces in the body under their influence. To prevent a negative impact on the living need to harmonize the physical vacuum. The action of these harmonization devices is based on the elimination of the asymmetry of physical vacuum components. Simple harmonizing device consists of several elements, which were recorded the left and right torsion fields before. We have developed the device of the physical vacuum harmonization. When the device is a plug in  the physical vacuum is harmonized. It is necessary to pay much attention to theoretical issues of influence of technical torsion fields on the human body and alive and biomedical research, one of the main areas of the study natural and technical torsion fields must be brought to a new level

Biography:

EO Okoro is a physician with a research degree in pharmacology. He is Professor of Medicine and honorary consultant physician to university of Ilorin teaching hospital (UITH) and has over 30 publications in type2diabetes and hypertension. Professor Okoro was involved in setting up a hospital based regional pharmacovigilance centre that serves over 20 million people at UITH as a member of Nigeria National Drug Safety Advisory Committee

Abstract:

Precision medicine can improve care and lower cost by matching each group/ individual with what work best for each.  Already even without widespread genetic testing, mortality - related to type2diabetes / hypertension is plunging in Europe /North America from effective interventions. In contrast mortality remains alarmingly high locally just as the same anti-atherosclerotic therapies dominate Nigeria market.  Coincidentally,  unlike in Europe/North America  where over  70% of deaths in  type2diabetes/hypertension usually  result  from atherosclerosis no more than 0.6-2% of affected  Nigerians generally experience  such outcomes despite frequent ( 70-90%) dyslipidaemia  including elevated cholesterol in  such groups.  Intriguingly , an unusual cooperation between elements in academia,  industry and  regulators  means  this  biologic advantage  for delivering  superior cardiovascular care in type2diabetes  at a  lower cost compared to jurisdictions where occlusive atherosclerosis is  frequent is being overlooked .The result is an epidemic of overtreatment which expose  the affected population to the risk of  paying   the highest possible cost for the worst possible care when  cheaper alternatives that  can save more lives  through better  BP reduction are widely available .  Specifically, the astronomical rise in  outpatient treatment cost  from under  N2000 in 2000  to   N56,2450  monthly  as at 2013  results predominantly (> 90% )  from  interventions/ tests of largely unproven health benefits to local  population but couched as  national best practice.    And Nigeria remains the largest health market of blacks globally currently estimated at 190 million and projected to become the third most populous nation by 2050 after India and China.  With 30-40% of this population having hypertension /type2diabetes this is a huge marketing opportunity for effective/affordable treatments that can keep poor people alive and turn them into paying customers.

Biography:

Xi Huang has completed his PhD from Fouth Military Medical University(FMMU)  in 1995 and postdoctoral studies from Xiyuan Hospital, China Academy of Chinese Medicine Science in 1998 respectively. He is the director and Professor of Institute of TCM-related depressive comorbidity, Nanjing University of Chinese Medicine(NUCM). He is respectively Lead Clinician in Xijing Hospital of FMMU, West China Hospital of Sichuan University and Xiangya Hospital of Central South University of China. He has got 9 funds of National Natural Science Foundations of China. Among > 200 papers as corresponding author, 41 involve in TCM in SCI journals. He is > 10 editorial board members or correspondence reviewer of repute journal. He also is Chairmen of Basic Theory Committee of China Association of Integrated Medicine

Abstract:

Considerably clinical and experimental evidences accumulated show bidirectionally interactions between FGIDs(functional gastrointestinal disorders) and depression following stress via gut-brain signals including α2-AR, ghrelin(Ghr), IL-1, NO and kynurenine(AGINK). All AGINK signals have not been pharmacodynamically integrated by simultaneous antidepressants and mediating gut motor(A&M) because there are no A&M agents. In fact, such A&M effects by Shugan of TCM formulae often occur separately in different publications. We aim to elucidate and integrate gut-brain signals following stress via evidences from  literature  and  simultaneous  A&M compounds from Shugan’s herbs in our previous and recent studies. Available conclusions include: 1)AGINK are better gut-brain signals than other molecules, supported by more evidences  separately involved in depression and FGIDs. Of these, no one had been integrated by  simultaneous A&M pharmacology before 2013; 2)Such action has been theoretically described for thousands of years and separately occurred for hundreds of years among several decades of TCM formulae and their compounds. However, no one had been tested its synchronous A&M efficacy before; 3) For the first time: via mediating HPA axis hormones, 5-HT/NA/ DA(involved in antidepressants) and Ghr(involved in prokinetic) concentration, concurrent A&M(the latter action  is prokinetic) efficacy induced by Chaihu-shugan-san(CSS) formula and its absorbed compound ferulic acid happened when compared by us in 2011. Such antidepressant and prokinetic(A&P) action also occur after oral meranzin hydrate(MH), hesperidin, peoniflorin and Senkyunolide to rat swept forcedly in our recent works, mediating by IL-1, 10β, oxidation stress, kynurenine and BDNF/p-mTOR, specially AMPA-ERK1/2-BDNF pathway for fast antidepressant without side effect similar to Ketamine. 4)α2-AR of disorder in gut-brain axis following FST to rat was integrated by MH-produced simultaneous A&P pharmacology, suggesting first  shared molecular  of A&P. Second shared molecular is Ghr. Shugan- and A&P-integrated shared molecules highlight personalized overlap of depression and FGIDs, suggesting potentially clinical biomarker in future.

Biography:

Ms. Sadaf Badar received her undergraduate and graduate degrees in Biochemistry/ Molecular Biology from Pakistan. She got a full scholarship from University of Verona where she  has completed her PhD at the age of 31 years in Clinical Proteomics. She has many research publications, poster and oral presentations. Currently, she is serving as an Assistant Professor at Govt. College University Lahore, Pakistan

Abstract:

Hereditary Hemochromatosis (HH), one of the commonest genetic disorder in Caucasians, is mainly associated to homozygosity for the C282Y mutation in the HFE gene, which is highly prevalent (allele frequency up to near 10% in Northern Europe) and easily detectable through a widely available "first level" molecular test. However, in certain geographical regions like the Mediterranean area, up to 30% of patients with a HH phenotype has a negative or non-diagnostic (i.e. simple heterozygosity) test, because of a known heterogeneity involving at least four other genes (HAMP, HJV, TFR2, and SLC40A1). Mutations in such genes are generally rare/private, making the diagnosis of atypical HH essentially a matter of exclusion in clinical practice (from here the term of "non-HFE" HH), unless cumbersome traditional sequencing is applied. We developed a Next Generation Sequencing (NGS)-based test targeting the five HH genes, and applied it to patients with clinically relevant iron overload (IO) and a non-diagnostic first level genetic test. We identified several mutations, some of which were novel (i.e. HFE W163X, HAMP R59X, and TFR2 D555N) and allowed molecular reclassification of "non-HFE" HH clinical diagnosis, particularly in some highly selected IO patients without concurring acquired risk factors. This NGS-based "second level" genetic test may represent a useful tool for molecular diagnosis of HH in patients in whom HH phenotype remains unexplained after the search of common HFE mutations